1. Subcutaneous delivery of tauroursodeoxycholic acid rescues the cone photoreceptors in degenerative retina: A promising therapeutic molecule for retinopathy.
- Author
-
Tao Y, Dong X, Lu X, Qu Y, Wang C, Peng G, and Zhang J
- Subjects
- Animals, Apoptosis drug effects, Disease Models, Animal, Female, Male, Methylnitrosourea pharmacology, Mice, Mice, Inbred C57BL, Oxidative Stress drug effects, Retinal Ganglion Cells drug effects, Electroretinography drug effects, Photoreceptor Cells, Vertebrate drug effects, Retina drug effects, Retinal Cone Photoreceptor Cells drug effects, Retinal Degeneration drug therapy, Taurochenodeoxycholic Acid pharmacology
- Abstract
Inherited retinal degeneration (RD) comprises a heterogeneous group of retinopathies that rank among the main causes of blindness. Tauroursodeoxycholic acid (TUDCA) is taurine conjugate hydrophilic bile acid that demonstrates profound protective effects against a series of neurodegenerative diseases related to oxidative stress. This study sought to evaluate the TUDCA induced effects of on a pharmacologically induced RD animal model by electroretinogram (ERG) examination, behavior tests, morphological analysis and immunochemistry assay. Massive photoreceptor degeneration in mice retina was induced by an intraperitoneal administration of N-methyl-N-nitrosourea(MNU). Subcutaneous delivery of TUDCA inhibits effectively the photoreceptor loss and visual impairments in the MNU administered mice. In the retinal flat-mounts of TUDCA treated mice, the cone photoreceptors were efficiently preserved. Furthermore, the multi-electrodes array (MEA) was used to detect the firing activities of retinal ganglion cells within the inner retinal circuits. TUDCA therapy could restrain the spontaneous firing response, enhance the light induced firing response, and preserve the basic configurations of ON-OFF signal pathway in degenerative retinas. Our MEA assay provided an example to evaluate the potency of pharmacological compounds on retinal plasticity. TUDCA affords these protective effects by modulating apoptosis and alleviating oxidative stress in the degenerative retina. In conclusion, TUDCA therapy can ameliorate the photoreceptor degeneration and rectify the abnormities in visual signal transmission. These findings suggest that TUDCA might act as a potential medication for these retinopathies with progressive photoreceptor degeneration., (Copyright © 2019 Tangdu Hospital, Fourth Military Medical University. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF